How to Read Your Hormone Lab Results: A Patient's Guide

What a Reference Range Actually Means

A reference range represents the central 95% of values found in a population of apparently healthy people. It does not define "optimal" for every individual. Two standard deviations above and below the mean capture most of the bell curve, but a person at the 3rd percentile and a person at the 97th percentile can both be labeled "normal" despite very different clinical pictures.

The Endocrine Society's 2014 position statement on laboratory testing emphasized that reference ranges "are method-dependent and population-dependent" and should not be used as standalone diagnostic cutoffs [1]. Your lab's printed range reflects the assay platform, the demographic mix used to build the interval, and statistical convention. It is not a verdict. A value of 4.1 mIU/L for TSH might be flagged as "high" at one lab and fall within range at another whose upper limit is 4.5.

Age, sex, body composition, time of day, and fasting status all shift hormone concentrations. A 25-year-old male and a 70-year-old male share the same testosterone reference interval on many lab reports, even though population-level data show a roughly 1 to 2% annual decline in total testosterone after age 30 [2]. Interpreting your results requires knowing what variables shaped the number on the page.

The Thyroid Panel: TSH, Free T4, and Free T3

TSH (thyroid-stimulating hormone) is the first-line screening marker. The American Thyroid Association (ATA) 2014 guidelines recommend TSH as the initial test for suspected thyroid dysfunction because the pituitary amplifies small changes in circulating thyroid hormone into large swings in TSH output [3]. A TSH of 0.4 to 4.0 mIU/L is the conventional reference interval, but the ATA has acknowledged ongoing debate about whether the upper limit should be closer to 2.5 mIU/L, particularly in younger adults without thyroid antibodies.

Free T4 (thyroxine) measures the unbound, biologically available fraction of the main thyroid hormone. Most labs report a range near 0.8 to 1.8 ng/dL. Free T3 (triiodothyronine) is the more metabolically active hormone, with a typical range of 2.3 to 4.2 pg/mL. Not every provider orders free T3 routinely. The 2012 ATA/AACE guidelines for hypothyroidism note that free T3 can be helpful when TSH and free T4 results do not explain persistent symptoms [4].

Pattern recognition matters more than any single number. A high TSH paired with a low free T4 points toward primary hypothyroidism. A suppressed TSH with an elevated free T4 suggests hyperthyroidism. A normal TSH with a low-normal free T4 and a low free T3 might indicate poor T4-to-T3 conversion, a pattern some clinicians investigate with reverse T3 testing [3].

Thyroid peroxidase (TPO) antibodies add diagnostic context. Roughly 90% of Hashimoto's thyroiditis cases show elevated TPO antibodies [5]. If your TSH is creeping upward and your TPO antibodies are positive, your clinician may monitor more frequently or initiate levothyroxine earlier than they would in antibody-negative subclinical hypothyroidism.

Testosterone: Total, Free, and Bioavailable

The American Urological Association (AUA) 2018 guideline defines testosterone deficiency as a total testosterone consistently below 300 ng/dL, measured on at least two morning fasting samples [6]. "Morning" matters because testosterone peaks between 7 and 10 AM and can drop 20 to 25% by late afternoon. A blood draw at 3 PM could produce a misleadingly low reading.

Total testosterone includes hormone bound to sex hormone-binding globulin (SHBG), hormone bound loosely to albumin, and a small free fraction (typically 1 to 3% of total). High SHBG, common in aging, hyperthyroidism, and oral estrogen use, binds more testosterone and reduces the amount available to tissues. This is why a total testosterone of 450 ng/dL with an SHBG of 80 nmol/L may produce symptoms of deficiency that the same total testosterone with an SHBG of 30 nmol/L would not.

Free testosterone is measured directly by equilibrium dialysis (the gold standard) or calculated using the Vermeulen formula from total testosterone, SHBG, and albumin. The calculated free testosterone method is widely available and correlates well with dialysis in most clinical settings [7]. If your report lists "free testosterone by analog assay," be aware that this method is considered less reliable by the Endocrine Society [1].

Dr. Shalender Bhasin, whose lab established much of the normative data for male testosterone ranges, has stated: "The diagnosis of androgen deficiency should be made only in men with consistent symptoms and unequivocally low serum testosterone levels" [2]. A single borderline result does not warrant treatment without clinical correlation.

Estradiol, Progesterone, and the Female Hormone Panel

Estradiol (E2) fluctuates dramatically across the menstrual cycle. During the early follicular phase, expect levels between 15 and 60 pg/mL. Around ovulation, estradiol can surge to 200 to 350 pg/mL before settling into a luteal plateau [8]. A random estradiol level without cycle-day context is difficult to interpret in premenopausal women. For perimenopausal and postmenopausal women, the North American Menopause Society (NAMS) notes that persistently low estradiol (below 20 pg/mL) combined with an FSH above 30 mIU/mL is consistent with menopause [9].

Progesterone testing is most useful in the mid-luteal phase (approximately day 21 of a 28-day cycle). A level above 3 ng/mL generally confirms ovulation occurred. Values above 10 ng/mL suggest a well-functioning corpus luteum [8]. Testing progesterone on cycle day 5 will almost always yield a low number regardless of ovulatory status, making timing essential.

FSH and LH provide the pituitary perspective. An FSH-to-LH ratio greater than 2:1, especially in a woman under 40, may raise suspicion for diminished ovarian reserve. Anti-Mullerian hormone (AMH) and antral follicle count via ultrasound are now preferred markers for ovarian reserve assessment per ASRM guidance, but FSH drawn on cycle day 3 remains part of many fertility evaluations [10].

For women on hormone replacement therapy, the goal is symptom resolution guided by clinical response. NAMS 2022 position statement emphasizes that "treatment should be individualized using clinical judgment" rather than targeting a specific estradiol number on lab work [9]. Routine monitoring of estradiol levels during HRT is optional but can help clinicians adjust dosing when symptoms are ambiguous.

Adrenal Markers: Cortisol and DHEA-S

Morning cortisol, drawn between 7 and 9 AM after overnight fasting, normally falls between 6 and 18 mcg/dL. Values below 3 mcg/dL raise concern for adrenal insufficiency and typically prompt an ACTH stimulation test [11]. Values above 20 mcg/dL in a morning sample, or a failure to suppress below 1.8 mcg/dL after a 1 mg overnight dexamethasone suppression test, warrant evaluation for Cushing's syndrome.

DHEA-S (dehydroepiandrosterone sulfate) is the most abundant circulating steroid hormone and serves as a precursor for both testosterone and estradiol. Unlike cortisol, DHEA-S has a long half-life and minimal diurnal variation, making it a stable single-draw marker. Reference ranges are heavily age-stratified. A 25-year-old woman might have a DHEA-S of 200 to 400 mcg/dL, while a 65-year-old woman's expected range drops to 20 to 130 mcg/dL [12]. Comparing your value to a non-age-adjusted range can create unnecessary alarm.

Salivary cortisol testing has gained popularity for assessing the diurnal cortisol curve (multiple samples across a day). The Endocrine Society's 2008 guideline on Cushing's diagnosis lists late-night salivary cortisol as one of three recommended initial screening tests, alongside 24-hour urinary free cortisol and the overnight dexamethasone suppression test [11].

Insulin, Glucose, and Metabolic Hormones

Fasting insulin is not part of most standard metabolic panels, but it provides early insight into insulin resistance before fasting glucose rises. A fasting insulin above 10 to 12 mcIU/mL, even with a normal fasting glucose, may indicate early metabolic dysfunction. The HOMA-IR calculation (fasting insulin x fasting glucose / 405) offers a rough estimate of insulin resistance. A HOMA-IR above 2.0 is commonly used as a threshold for clinical concern, though this cutoff varies by population [13].

Hemoglobin A1c reflects average blood glucose over approximately 90 days. The American Diabetes Association defines prediabetes as an A1c of 5.7 to 6.4% and diabetes at 6.5% or above [14]. One often-overlooked caveat: conditions that alter red blood cell lifespan (iron deficiency anemia, hemoglobinopathies, recent transfusion) can shift A1c independently of actual glucose control. In a cross-sectional analysis of NHANES data (N=15,934), iron deficiency without anemia was associated with A1c values approximately 0.2% higher than expected based on measured glucose [15].

GLP-1 receptor agonists like semaglutide affect several metabolic lab markers during treatment. In the STEP-1 trial (N=1,961), participants on semaglutide 2.4 mg showed reductions in fasting insulin alongside 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [16]. Clinicians monitoring patients on GLP-1 therapy should expect shifts in fasting insulin, HOMA-IR, and sometimes A1c that reflect improved insulin sensitivity rather than a primary hormonal disorder.

Practical Tips for Getting Accurate Results

Test timing affects accuracy for nearly every hormone. Draw testosterone and cortisol between 7 and 9 AM after an 8-hour fast. For thyroid panels, morning testing before taking levothyroxine (if prescribed) prevents a transient spike in free T4 from the absorbed dose. The ATA recommends waiting at least 4 to 6 weeks after a dose change before rechecking TSH, because the pituitary needs time to re-equilibrate [3].

Biotin supplementation interferes with many immunoassays. The FDA issued a 2017 safety communication warning that high-dose biotin (5 to 10 mg/day, common in hair and nail supplements) can cause falsely low TSH and falsely high free T4, mimicking Graves' disease on paper [17]. Stop biotin at least 48 to 72 hours before any hormone blood draw.

Ask your lab for the same assay platform each time you retest. Switching from one lab's electrochemiluminescence assay to another lab's liquid chromatography-tandem mass spectrometry (LC-MS/MS) method can shift your baseline. The Endocrine Society's 2010 position paper on testosterone assay standardization noted that between-method variability for total testosterone can exceed 20% [1].

Dr. Frances Hayes, an endocrinologist at Massachusetts General Hospital, has noted: "The most common mistake patients make is comparing a number from one lab to a range from a different lab's report they found online" [1]. Always use the reference range printed on your own report for initial orientation, then discuss clinical context with your provider.

Keep a personal log. Record the date, the fasting status, the time of draw, any medications taken that morning, and the lab used. Over time, trends in your own values tell a far more useful story than any single snapshot compared to a population average.

When to Retest and When to Act

A single abnormal hormone value rarely justifies treatment. The AUA requires two separate morning testosterone readings below 300 ng/dL before diagnosing deficiency [6]. For thyroid function, the ATA recommends confirming an elevated TSH with a repeat draw in 6 to 12 weeks for subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with a normal free T4), because transient TSH elevations occur during illness recovery, stress, and seasonal variation [3].

Act promptly when results are severely out of range. A TSH above 10 mIU/L with a low free T4 warrants treatment discussion at the first visit, not a 3-month recheck. A total testosterone below 150 ng/dL with symptoms of hypogonadism should trigger same-visit evaluation for secondary causes (pituitary MRI, prolactin, LH, FSH) rather than a watch-and-wait approach.

Bring your results to a clinician who treats the relevant condition regularly. A borderline TSH of 5.2 mIU/L with fatigue, weight gain, and positive TPO antibodies may mean one thing to a primary care physician seeing it for the first time and something quite different to an endocrinologist who manages 40 thyroid patients per week. Context, pattern, and clinical correlation convert raw numbers into a treatment plan.